Bromonordiazepam Blister - 10x 2.5mg
Bromonordiazepam Blister - 10x 2.5mg Price range: € 25,90 through € 218,75
Back to products
Flubromazepam Pellets - 8mg
Flubromazepam Pellets - 8mg Price range: € 15,00 through € 200,00

Bromonordiazepam Powder

Price range: € 60,00 through € 420,00

Bromonordiazepam Powder is described as a crystalline research material containing bromonordiazepam, a brominated 1,4-benzodiazepine-related compound.

The source also identifies the substance as desalkyl-gidazepam, a metabolite associated with gidazepam.

The supplied specifications report the chemical name 7-bromo-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one, CAS number 2894-61-3, molecular formula C15H11BrN2O, and molecular weight approximately 315.16 g/mol.

The reported presentation is white to off-white crystalline powder supplied in nominal 1 g portions.

The source claims ingredient purity of at least 98%, independent analytical testing, and full batch traceability.

No actual batch-specific Certificate of Analysis, impurity profile, or independent laboratory report was supplied.

The reported identity, purity, appearance, and packaging specifications therefore require verification.

Bromonordiazepam is associated with benzodiazepine-related hazards, including sedation, impaired coordination, dependence, and potentially dangerous interactions with other central nervous system depressants.

The material is not established as a certified reference standard or approved pharmaceutical product.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-P-12467 Category:
Description

Bromonordiazepam Powder 315g – Research Material Information

Bromonordiazepam Powder 315g– Product Overview

Bromonordiazepam Powder 315g is the supplied catalog designation for a crystalline research material described as containing bromonordiazepam.

The source identifies the substance as a brominated 1,4-benzodiazepine-related compound and associates it with the metabolism of gidazepam.

The reported product presentation is a nominal 1 g portion of crystalline powder.

This is a packaging claim rather than an independently verified net-content measurement.

The source places the material within laboratory contexts involving benzodiazepine chemical identity, structural characterization, and analytical documentation.

No actual batch-specific Certificate of Analysis, independent laboratory report, or finished-product inspection record was supplied.

The material is not established as a certified reference standard or approved pharmaceutical product.

Chemical Identity & Classification

Bromonordiazepam powder is described as a brominated 1,4-benzodiazepine with a 7-bromo-5-phenyl substitution pattern.

The source provides the following specifications:

  • Reported chemical name: Bromonordiazepam
  • Reported relationship: Desalkyl-gidazepam metabolite
  • Supplied systematic name: 7-Bromo-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
  • Reported CAS number: 2894-61-3
  • Reported molecular formula: C15H11BrN2O
  • Reported molecular weight: 315.16 g/mol
  • Reported form: Crystalline powder
  • Nominal portion: 1 g
  • Intended designation: Research Use Only

The supplied molecular formula calculates to approximately 315.17 g/mol, consistent with the reported molecular weight within rounding.

However, numerical consistency alone does not establish the identity or purity of the supplied material.

The CAS number, chemical structure, metabolite designation, and actual chemical form should be verified against authoritative records and batch-specific documentation.

Public chemical-reference information can be reviewed through PubChem, ensuring that any selected record corresponds to the intended compound.

Chemical & Physical Characteristics

The source describes the material as a white to off-white fine crystalline powder.

No actual product inspection report, particle-size distribution, crystal-form characterization, or verified physical specification was supplied.

The source refers to solubility and stability as analytical considerations.

However, no validated product-specific measurements were provided.

The source also does not establish the impurity profile, residual moisture content, or long-term stability of the supplied powder.

Descriptions of appearance and physical form should therefore be treated as source-reported information rather than verified batch characteristics.

Purity & Analytical Verification

The source claims ingredient purity of at least 98% by HPLC.

It also refers to HPLC, mass spectrometry, and NMR spectroscopy for identity confirmation.

No chromatogram, mass spectrum, NMR spectrum, impurity report, or batch-specific Certificate of Analysis was supplied.

The claimed purity therefore remains unverified.

A purity percentage alone does not establish complete chemical identity, impurity characterization, or quantitative reference-material suitability.

The source describes analytical laboratory contexts, but no validated quantitative reference value or certified reference-material documentation was supplied.

The material should not be described as a certified analytical standard without appropriate supporting records.

Quality Control & Batch Integrity

The source claims third-party laboratory testing, batch traceability, controlled manufacturing, and residual-solvent analysis.

These claims are not supported by supplied batch-specific documentation.

No independent laboratory report, manufacturing record, residual-solvent dataset, or traceability record was provided.

A nominal 1 g package designation does not establish verified net content.

Ingredient purity, chemical identity, impurity profiling, and package quantity are distinct measurements.

The Research Use Only designation does not independently demonstrate certified quality or validated analytical performance.

Safety, Handling & Laboratory Precautions

Bromonordiazepam powder 315g is a benzodiazepine-related compound associated with central nervous system depressant hazards.

Potential risks include sedation, impaired coordination, dependence, withdrawal complications, and respiratory depression.

Combining benzodiazepine-related substances with opioids, alcohol, or other central nervous system depressants can substantially increase the risk of severe harm.

The source does not provide a verified product-specific Safety Data Sheet.

Institutional safety procedures should address restricted access, appropriate protective equipment, secure custody, accidental-exposure response, contamination prevention, and waste management.

The powder presentation does not imply suitability for human or animal administration.

Packaging, Labeling & Storage

The source describes nominal 1 g portions supplied in resealable, inert packaging.

No actual packaging specification, container-validation record, or verified net-content measurement was supplied.

The source recommends storage at approximately -20°C in a dry environment protected from light and moisture.

No validated finished-product stability study was provided to establish that temperature as a confirmed storage requirement.

The source does not establish a verified shelf life or packaging-protection performance.

Inventory records should distinguish nominal catalog specifications from verified batch information.

Intended Research Use & Market Positioning

The source places bromonordiazepam powder 315g within laboratory contexts involving benzodiazepine chemical identity, analytical characterization, and structural comparison.

No certified reference-material status or validated quantitative performance has been demonstrated.

The supplied Raw Lab Chems catalog references include Bromonordiazepam Pellets, Bromonordiazepam Powder 315g, and Bromonordiazepam Blister 10x 2.5mg.

These listings describe different product presentations.

Their formulation equivalence, ingredient purity, and finished-product analytical performance have not been independently established.

Catalog relationships should not be interpreted as evidence of interchangeable formulations or certified analytical status.

Ordering, Availability & Fulfillment

The source claims international shipping, tracking, customs documentation, and compliant transport.

No current inventory information, carrier authorization, shipment documentation, or verified delivery information was supplied.

The source also refers to IATA and DOT compliance.

No applicable dangerous-goods classification, transport assessment, or supporting compliance documentation was provided.

No claim is therefore made that worldwide shipment or customs clearance is universally available or legally authorized.

Bromonordiazepam may be controlled or otherwise restricted under applicable national and international laws.

Research-only labeling does not establish a legal exemption.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Bromonordiazepam is a benzodiazepine-related compound whose acquisition, possession, transportation, importation, exportation, and laboratory investigation may be regulated.

Institutions remain responsible for determining applicable legal requirements, obtaining necessary authorization, and maintaining appropriate laboratory safety and secure custody.

No therapeutic approval, consumer-use authorization, or certified analytical status is implied.

Additional information
Quantity (0.5 grams)

2

,

5

,

10

,

20

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Bromonordiazepam Powder”
Shipping & Delivery